M
M. Helen Huls
Researcher at Center for Cell and Gene Therapy
Publications - 14
Citations - 3263
M. Helen Huls is an academic researcher from Center for Cell and Gene Therapy. The author has contributed to research in topics: Immunotherapy & Cytotoxic T cell. The author has an hindex of 13, co-authored 14 publications receiving 3098 citations. Previous affiliations of M. Helen Huls include Boston Children's Hospital & Houston Methodist Hospital.
Papers
More filters
Journal ArticleDOI
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin Pule,Barbara Savoldo,G. Doug Myers,G. Doug Myers,Claudia Rossig,Heidi V. Russell,Heidi V. Russell,Gianpietro Dotti,Gianpietro Dotti,M. Helen Huls,Enli Liu,Adrian P. Gee,Adrian P. Gee,Zhuyong Mei,Eric Yvon,Heidi L. Weiss,Hao Liu,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Helen E. Heslop,Malcolm K. Brenner,Malcolm K. Brenner +22 more
TL;DR: It is shown in individuals with neuroblastoma that EBV-specific CTLs expressing a chimeric GD2-specific receptor indeed survive longer than T cells activated by the CD3-specific antibody OKT3 and expressing the same chimeric receptor but lacking virus specificity.
Journal ArticleDOI
Cytotoxic T lymphocyte therapy for epstein-barr virus+ Hodgkin's disease
Catherine M. Bollard,Catherine M. Bollard,Laura K. Aguilar,Karin Straathof,Benedikt Gahn,M. Helen Huls,Alexandra Rousseau,John W. Sixbey,M. Victoria Gresik,George Carrum,George Carrum,Melissa M. Hudson,Dagmar Dilloo,Adrian P. Gee,Adrian P. Gee,Malcolm K. Brenner,Malcolm K. Brenner,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Helen E. Heslop +20 more
TL;DR: The performance and fate of these human tumor antigen–specific T cells in vivo suggests that they might be of value for the treatment of EBV+ Hodgkin lymphoma.
Journal ArticleDOI
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes
Karin Straathof,Catherine M. Bollard,Catherine M. Bollard,Catherine M. Bollard,Uday R. Popat,M. Helen Huls,M. Helen Huls,M. Helen Huls,Teresita Lopez,Teresita Lopez,Teresita Lopez,M. Craig Morriss,M. Craig Morriss,M. Craig Morriss,Mary V. Gresik,Mary V. Gresik,Mary V. Gresik,Adrian P. Gee,Adrian P. Gee,Adrian P. Gee,Heidi V. Russell,Heidi V. Russell,Heidi V. Russell,Malcolm K. Brenner,Cliona M. Rooney,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop +27 more
TL;DR: It is demonstrated that EBV-specific cytotoxic T-cell lines can readily be generated from individuals with NPC, notwithstanding the patients' prior exposure to chemotherapy/radiation, and can be associated with significant antitumor activity.
Journal ArticleDOI
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.
Catherine M. Bollard,Stephen Gottschalk,Ann M. Leen,Heidi L. Weiss,Karin Straathof,George Carrum,Mariam Khalil,Meng-Fen Wu,M. Helen Huls,Chung-Che Chang,M. Victoria Gresik,Adrian P. Gee,Malcolm K. Brenner,Cliona M. Rooney,Helen E. Heslop +14 more
TL;DR: It is shown that it is possible to generate immune responses to weak tumor antigens by ex vivo genetic modification of APCs and the CTLs so produced can have substantial antitumor activity.
Journal ArticleDOI
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation.
Ingrid Kuehnle,M. Helen Huls,Zhensheng Liu,Micah Semmelmann,Robert A. Krance,Malcolm K. Brenner,Cliona M. Rooney,Helen E. Heslop +7 more
TL;DR: It is concluded that CD20 antibody may be a useful alternative treatment strategy in patients with EBV lymphoma after BMT, and 3 patients successfully and safely treated with rituximab, a CD20 monoclonal antibody are reported on.